Brown Advisory Securities LLC raised its stake in Pfizer, Inc. (NYSE:PFE) by 6.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,015 shares of the biopharmaceutical company’s stock after buying an additional 3,825 shares during the period. Brown Advisory Securities LLC’s holdings in Pfizer were worth $2,054,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. D Orazio & Associates Inc. increased its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the period. Stone House Investment Management LLC increased its position in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after buying an additional 66 shares during the period. Naples Global Advisors LLC increased its position in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after buying an additional 79 shares during the period. Pure Financial Advisors Inc. increased its position in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 84 shares during the period. Finally, Alpha Windward LLC increased its position in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 89 shares during the period. Institutional investors and hedge funds own 70.10% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.12% during trading on Thursday, reaching $33.41. 2,413,436 shares of the company’s stock traded hands. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.38. The stock has a 50-day moving average price of $33.44 and a 200 day moving average price of $33.30. The stock has a market capitalization of $199.39 billion, a P/E ratio of 24.44 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s dividend payout ratio is currently 94.12%.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/brown-advisory-securities-llc-increases-stake-in-pfizer-inc-pfe/1467943.html.

Several equities analysts have commented on the stock. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley restated a “neutral” rating and issued a $35.00 price target (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Finally, Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus target price of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.